Author:
Kussini Jacqueline,Kaisers Tabea,Sequeira Santos Antonio Manuel,Eming Rüdiger,Didona Dario
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Benesh G, Andriano TM, Cohen SR (2021) Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy. JAAD Case Rep 16:12–15
2. Berookhim B, Fischer HD, Weinberg JM (2004) Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 74:245–247
3. Bieber K, Sun S, Witte M, Kasprick A, Beltsiou F, Behnen M, Laskay T, Schulze FS, Pipi E, Reichhelm N, Pagel R, Zillikens D, Schmidt E, Sparwasser T, Kalies K, Ludwig RJ (2017) Regulatory T cells suppress inflammation and blistering in Pemphigoid diseases. Front Immunol 8:1628
4. Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A (2013) Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res 56:390–397
5. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621